| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
When paired with doxorubicin, LDCA (2-100 μM; 16-72 h) works in concert to improve growth inhibition and trigger mitochondria by enlisting the caspase cascade, limiting migration, and removing the melanoma cells' capacity for clonal growth. apoptosis was mediated [1].
|
|---|---|
| ln Vivo |
In mouse melanoma models, LDCA (2 mg/kg, intravenously, once on day 6) in combination with doxorubicin reduces carcinogenic progression, stops tumor growth kinetics, and enhances survival [1].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: B16-F10 Cell Tested Concentrations: 2-100 μM Incubation Duration: 72 h Experimental Results: Inhibits cell growth, has dose-dependent cytotoxicity, and has a strong synergistic effect with LDCA. Apoptosis analysis[1] Cell Types: B16-F10 Cell Tested Concentrations: 20 μM Incubation Duration: 24 hrs (hours) Experimental Results: When cells were exposed to LDCA, it resulted in 15% death and synergistically with doxorubicin, resulting in 40% melanoma Cell death. Immunofluorescence[1] Cell Types: B16-F10 Cell Tested Concentrations: 20 μM Incubation Duration: 16 hrs (hours) Experimental Results: Demonstration that combination with doxorubicin affects cell morphology, leading to condensation and fragmentation of nuclei. Cell migration assay [1] Cell Types: B16-F10 Cell Tested Concentrations: 20 μM Incubation Duration: 16 hrs (hours) Experimental Results: Dramatically limited the migration potential of B16-F10 cells. |
| Animal Protocol |
Animal/Disease Models: Melanoma tumor model [1]
Doses: 2 mg/kg Route of Administration: 2 mg/kg, intravenous (iv) (iv)injection, once on the 6th day. Experimental Results: Combined with doxorubicin, the survival ability of mice was Dramatically improved. , reduce tumor necrosis in mice. |
| References | |
| Additional Infomation |
See also: Acetamide (annotation moved to).
|
| Molecular Formula |
C8H5CL3FNO
|
|---|---|
| Molecular Weight |
256.49
|
| Exact Mass |
254.942
|
| CAS # |
349106-80-5
|
| PubChem CID |
4322881
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
215
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(NC1=CC=C(F)C(Cl)=C1)(=O)C(Cl)Cl
|
| InChi Key |
WZVDWCGCAQYINC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H5Cl3FNO/c9-5-3-4(1-2-6(5)12)13-8(14)7(10)11/h1-3,7H,(H,13,14)
|
| Chemical Name |
2,2-dichloro-N-(3-chloro-4-fluorophenyl)acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~389.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8988 mL | 19.4939 mL | 38.9879 mL | |
| 5 mM | 0.7798 mL | 3.8988 mL | 7.7976 mL | |
| 10 mM | 0.3899 mL | 1.9494 mL | 3.8988 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
